Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSD-2XX
- Development stage
- Preclinical
- Lead developer
- Mindstate Design Labs
- Modality
- Small Molecules
01
Overview
MSD-2XX is a preclinical-stage small molecule program being developed by Mindstate Design Labs. It is currently in the target discovery and validation phase. The program utilizes Mindstate's Osmanthus platform, a molecular-experience interface that maps molecular structure, polypharmacology, and pathway signaling onto drug-effect readouts to design specific psychoactive effects. MSD-2XX is designed as a single-molecule, multi-target therapeutic to produce a targeted range of psychoactive effects.
Beyond the preview
Go deeper on MSD-2XX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MSD-2XX.